INmune Bio Inc. Announces Attendance at the 2025 RBC Capital Markets Global Healthcare Conference...

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update...

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thurs...

INmune Bio Receives Favorable Patentability Opinion for CORDStrom™ Platform Technology...

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for C...

INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL P...

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update...

INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on Marc...

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer...

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORD...

INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans...